A therapy demonstrated to significantly extend maximum human lifespan enters Phase III clinical trials before

Question

Six frontier AI models put this at 9% by 16 Oct 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

9% — the median of 6 frontier models, resolving by 2031-10-16.

Answer

Gemini (Google): 8% — Regulators do not accept aging or maximum lifespan as an indication, forcing trials to target specific diseases instead. FDA trials require measurable endpoints on existing pathologies, not healthy lifespan extension which takes decades to evaluate. No current longevity candidate in Phase II (e.g., rapamycin or metformin/TAME) is primarily powered or designed for max lifespan. A formal regulatory pivot creating an approval pathway for biological aging biomarkers before 2029 would raise this above 25%.

Answer

Claude (Anthropic): 9% — Hinges on whether an aging-specific trial reaches Phase III with a lifespan-extension endpoint by 2031. No therapy has ever been proven to extend max human lifespan; current trials (rapamycin, metformin/TAME, senolytics) target biomarkers or healthspan, not max lifespan… Phase III aging trials face FDA's lack of recognized aging biomarker endpoints, and TAME itself remains stuck pre-Phase III after years of funding delays. A breakthrough FDA aging-endpoint ruling or a well-funded senolytic/gene-therapy sponsor advancing rapidly could flip this, but no such signal exists yet.

Answer

GPT (OpenAI): 18% — This hinges on whether a regulator accepts an aging/lifespan indication backed by credible late-stage human evidence. Phase III requires a sponsor, protocol, funding, and a recognized indication; aging itself is not FDA- or EMA-approved as one. No drug has yet shown a significant extension of maximum human lifespan, and validating that endpoint normally exceeds a four-year window. Odds rise sharply if a major regulator accepts surrogate endpoints for an anti-aging indication or a large metformin/rapamycin trial is redesigned for Phase III.

Answer

Grok (xAI): 3% — No human max-lifespan extension can be shown in time for a 2031 Phase III start. Demonstration requires humans exceeding ~122 y, data that cannot accrue by 2031. FDA/EMA Phase III needs prior human efficacy; animal max-LS data (rapamycin, senolytics) have never sufficed. Base rate is zero such agents; only a sudden validated supercentenarian cohort would shift this.

Answer

DeepSeek (DeepSeek): 12% — This turns on whether a geroprotective drug with hard mortality or lifespan endpoints clears Phase II and gets funded into Phase III within five years. No drug has ever shown maximum-lifespan extension in humans; the FDA has never approved an aging indication, so the endpoint itself is unvalidated. The leading candidates (rapamycin analogs, senolytics like dasatinib+quercetin, metformin's TAME) have stalled: TAME has sought funding since 2015 and still has no Phase… Most likely path is a repurposed drug like rapamycin or a senolytic advancing on a composite endpoint by 2029-2030, but Phase II mortality data would need to be striking…

Answer

Qwen (Alibaba): 2% — No therapy can be *demonstrated* to extend maximum human lifespan (~122 yrs) within 5 years; that requires decades of follow-up or a validated surrogate that doesn't yet exist. Maximum lifespan extension requires observing humans surpass ~122 years or a regulator-accepted surrogate; no such biomarker panel is validated for that endpoint as of… TAME (metformin) remains the closest candidate to a Phase III longevity trial but targets multimorbidity delay, not maximum lifespan, and still lacks full… Even under generous interpretation, no Phase II anti-aging result has shown effect sizes plausibly mapping to maximum lifespan extension; a breakthrough in validated…

A therapy demonstrated to significantly extend maximum human lifespan enters Phase III clinical trials before 2031.

What each one said

A therapy demonstrated to significantly extend maximum human lifespan enters Phase III clinical trials before 2031.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.